Search
NNZ-2591
go.drugbank.com/drugs/DB15601InvestigationalIt was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been
Roquinimex
go.drugbank.com/drugs/DB11366ExperimentalIts effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.
Gaboxadol
go.drugbank.com/drugs/DB06554InvestigationalIt acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives. … Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing
Gadolinium
go.drugbank.com/drugs/DB12091ApprovedInvestigationalWithdrawnGadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
NKX101
go.drugbank.com/drugs/DB18131InvestigationalNKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.
Synonyms: a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15Cimlanod
go.drugbank.com/drugs/DB14983InvestigationalCimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)
Paramethasone
go.drugbank.com/drugs/DB01384ExperimentalIt has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less
APL-9
go.drugbank.com/drugs/DB16460InvestigationalAPL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.
Flupirtine
go.drugbank.com/drugs/DB06623InvestigationalIt is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
Honey
go.drugbank.com/drugs/DB14242ApprovedInvestigationalHoney is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.